Ultrasound-Guided Modified Pectoral Plane (PECS II) Block Versus Midpoint Transverse Process to Pleura (MTP) Block for Postoperative Analgesia of Modified Radical Mastectomy

This study aims to compare the analgesic efficacies of the modified pectoral plane block (PECS II) and the midpoint transverse process to pleura block (MTP), after modified radical mastectomy (MRM) surgery during the first 24 hour post-operatively by using the Visual Analogue Scale.

Start Date01 Mar 2025

Sponsor / Collaborator

Ain Shams University

NCT06769932

/ Not yet recruitingNot ApplicableIIT

Relationship Between Muscle Mass in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose Required for Maintaining Deep Neuromuscular Blockage: a Prospective Observational Study.

With the recent development of image analysis and artificial intelligence, it has become possible to measure the muscle volume from preoperative computed tomography (CT) images. Therefore, in this study, the investigators quantify the muscle volume from preoperative CT images and analyze the correlation with the dose of neuromuscular blocking agent, rocuronium, required for maintaining deep neuromuscular blockade.

Start Date07 Jan 2025

Sponsor / Collaborator

Seoul National University Bundang Hospital

NCT06740877

/ Not yet recruitingNot ApplicableIIT

Relationship Between Skeletal Muscle Index in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose Required for Maintaining Deep Neuromuscular Blockage: a Prospective Observational Study.

With the recent development of image analysis, it has become possible to measure the skeletal muscle index representing the subject's muscle mass from preoperative computed tomography (CT) images. Therefore, in this study, the investigators quantify the skeletal muscle index from preoperative CT images and analyze the correlation with the dose of neuromuscular blocking agent, rocuronium, required for maintaining deep neuromuscular blockade.

Start Date25 Dec 2024

Sponsor / Collaborator

Seoul National University Bundang Hospital

100 Clinical Results associated with Reversal of Neuromuscular Blockade

100 Translational Medicine associated with Reversal of Neuromuscular Blockade

0 Patents (Medical) associated with Reversal of Neuromuscular Blockade

Literatures (Medical) associated with Reversal of Neuromuscular Blockade

31 Oct 2024·Anesthesia and Pain Medicine

Sugammadex for our little ones: a brief narrative review

Review

Author: Lee, Soomin ; Chung, Woosuk

Sugammadex, the first noncompetitive antagonist developed for the reversal of neuromuscular blockade (NMB), is one of the few drugs that has revolutionized anesthetic practice. However, the use of sugammadex for children between the ages of 2 and 17 years has only recently been approved and is currently not approved for children under the age of 2 years. Although the precision and reliability of reversal of NMB with sugammadex are of great benefit in pediatric anesthesia, several important questions remain regarding its use in our youngest patients. In this brief narrative review, we aim to provide an overview of the key considerations and potential challenges that anesthesiologists often face when using sugammadex in pediatric patients.

01 Oct 2023·Journal of dental anesthesia and pain medicine

Sugammadex-induced bronchospasm: a case report.

Author: Kim, Saeyoung ; Kim, Ji Hyun ; Jung, Hoon ; Choo, Hyojun

Sugammadex has shown faster reversal of steroidal neuromuscular blockade (NMB) than neostigmine, a traditional reversal agent for NMB, even in the intense block phase. This efficiency is possible because of the unique mechanism of action by encapsulating the NMB molecules. Therefore, with the use of sugammadex, we can also expect to avoid direct interactions with the cholinergic system and its subsequent side effects, which are disadvantages of traditional drugs. However, despite these benefits and US Food and Drug Administration (FDA) approval in 2015, rare adverse events associated with sugammadex have been reported. Herein, we report a case of bronchospasm that developed immediately after sugammadex administration.

31 Jan 2023·Anesthesia and Pain Medicine

Sugammadex administration in patients with end-stage renal disease: a narrative review with recommendations

Review

Author: Oh, Seok Kyeong ; Lim, Byung Gun

Due to unknown safety concerns, sugammadex should not be administered to patients with end-stage renal disease (ESRD). However, because the supply of benzylisoquinolinium-type neuromuscular blocking agents (NMBAs) has been discontinued, rocuronium is the only non-depolarizing NMBA that can be used in clinical settings in some countries, including South Korea. The administration of sugammadex cannot be avoided to achieve rapid and complete neuromuscular recovery in patients with ESRD or renal transplantation after rocuronium administration. Although there has been a limited number of clinical studies involving the use of sugammadex in patients with ESRD, studies have shown that sugammadex can effectively and safely reverse rocuronium-induced neuromuscular blockade (NMB) in patients with ESRD, however recovery of neuromuscular function in patients with ESRD is slower than in patients with normal renal function. Nonetheless, safety-concerns are yet to be addressed. Considering the small number of clinical studies, high heterogeneity among studies, and insufficient safety information, more extensive data on the efficacy and safety of sugammadex in patients with ESRD are needed. In particular, it is important to secure data on safety, including residual NMB after surgery, recurarization and cardiorespiratory complications, anaphylactic reactions, and long-term morbidity and mortality. Furthermore, anesthesiologists should remember that performing proper quantitative neuromuscular monitoring and neuromuscular management based on the monitoring signs are the most essential requirements when using sugammadex in patients with ESRD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Reversal of Neuromuscular Blockade

Basic Info

Related

Analysis